NUVECTIS PHARMA INC (NVCT) Stock Income Statement
NASDAQ:NVCT - Nasdaq - US67080T1088 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 19.85M | 22.90M | 19.23M | 12.89M | 10.00K | |||
| Research and Development | 12.92M | 15.38M | 13.23M | 9.55M | 0.00 | |||
| Selling, General, and Administrative Expenses | 6.93M | 7.52M | 6.01M | 3.35M | 10.00K | |||
| Operating Income | -19.85M | -22.90M | -19.23M | -12.89M | -10.00K | |||
| Interest Income/Expense | 847.00K | 637.00K | 150.00K | 0.00 | N/A | |||
| Income Before Taxes | -19.00M | -22.26M | -19.09M | -12.89M | -10.00K | |||
| Net Income | -19.00M | -22.26M | -19.09M | -12.89M | -10.00K | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.11 | -1.43 | -1.51 | -53.70 | -0.04 | |||
| Non GAAP EPS | -1.11 | -1.43 | N/A | N/A | N/A | |||
| Statistics | ||||||||
All data in USD